US-based Certara, Inc., a global leader in model-informed drug development (MIDD), has announced a new distributor agreement with China's Cloudscientific. The agreement brings Certara’s leading discovery informatics platform, D360, and Certara’s secure and flexible GPT offering, Certara.AI, to China‘s growing research and development community.  

The D360 scientific informatics platform delivers self-service access to data and integrated scientific intelligence resulting in timelier insights for smarter and faster decisions. It is used by more than 6,500 scientists, including five of the top ten biopharmaceutical companies, to advance discovery research for small molecule and biological candidates.   

Certara.AI deploys life science-specific GPTs across drug development from early discovery to clinical trials to regulatory submission.  

As the pharmaceutical industry races to develop new and effective drugs and treatments, China has emerged as an R&D hub. China’s expenditure reached 2.4% of its GDP in 2020 with 24 drugs approved in the first half of 2023.  

This partnership will enable Cloudscientific to provide researchers with the advanced tools and insights they need to accelerate their drug discovery and development efforts.